Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class ...

With the introduction of adaptive deep brain stimulation (aDBS) for Parkinson's disease, new questions emerge regarding who, why, and how to treat. This paper outlines the pathophysiological rationale ...

Despite their differences, Alzheimer’s disease and Parkinson’s disease share several risk factors and mechanisms of neuronal damage. Both also feature a phase that precedes the appearance of symptoms ...

Your T cells work hard to fight disease. Unfortunately, "friendly fire" from T cells can sometimes harm the body's healthy tissues. For people with autoimmune disease, T cell reactivity is a big ...